The Company’s mission is to address critical unmet needs in ophthalmology by overcoming the shortcomings of current therapeutic options in this area. The objective is not only to improve short and long term therapeutic outcomes, but also enhance compliance and improve tolerability.

This achieve this goal, Eyevensys has developed a novel therapeutic approach based on the electro-transfection into the ciliary muscle of plasmids encoding therapeutic proteins. This leads to the sustained expression of such therapeutic agents in ocular media over extended periods, alleviating the pain of repeated invasive administrations.